Back to Explore

P05.org

Weekly structural analysis on pharmaceutical royalty financing. Deal mechanics, legal events, fund positioning, primary sources.

167

Subscribers

On the social web

Subscribe via Mastodon, Threads, Flipboard, or any social web platform.

Latest Posts

The Skinny-Label Question Comes to One First Street: What Hikma v. Amarin Means for Pharmaceutical Royalty Financing

Sebastian Gensior · 30 Apr 2026

Anti-Dilution Mechanics in Synthetic Royalty Agreements: Protecting Investor Economics When the Underlying Asset Gets Sublicensed, Reformulated, or Combined

Sebastian Gensior · 29 Apr 2026

Will GLP-1 Royalties Deliver What They Promised? Deal Economics Under a Repricing Regime

Sebastian Gensior · 28 Apr 2026

Contributors

Sebastian Gensior

Blending technical expertise with big-picture vision. Innovation in AI, biotech, and VC, Running Capital for Cures. Connect: https://www.linkedin.com/in/sgensior/

P05.org

Contributors

Sebastian Gensior

More from Finance

Moodfolio

Save Money in Winnipeg

VISARY.io - Investment Meditations

FitGap Finance